

**SuperMEN1**

## **ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY**

### **Editorial Board:**

**NATHAN BACK**, *State University of New York at Buffalo*

**IRUN R. COHEN**, *The Weizmann Institute of Science*

**ABEL LAJTHA**, *N.S. Kline Institute for Psychiatric Research*

**JOHN D. LAMBRIS**, *University of Pennsylvania*

**RODOLFO PAOLETTI**, *University of Milan*

---

### **Recent Volumes in this Series**

Volume 660

**PARAOXONASES IN INFLAMMATION, INFECTION, AND TOXICOLOGY**

Edited by Srinu Reddy

Volume 661

**MEMBRANE RECEPTORS, CHANNELS AND TRANSPORTERS  
IN PULMONARY CIRCULATION**

Edited by Jason X.-J. Yuan, and Jeremy P.T. Ward

Volume 662

**OXYGEN TRANSPORT TO TISSUE XXXI**

Edited by Duane F. Bruley, and Eiji Takahasi

Volume 663

**STRUCTURE AND FUNCTION OF THE NEURAL CELLADHESION MOLECULE  
NCAM**

Edited by Vladimir Berezin

Volume 664

**RETINAL DEGENERATIVE DISEASES**

Edited by Robert E. Anderson, Joe G. Hollyfield, and Matthew M. LaVail

Volume 665

**FORKHEAD TRANSCRIPTION FACTORS**

Edited by Kenneth Maiese

Volume 666

**PATHOGEN-DERIVED IMMUNOMODULATORY MOLECULES**

Edited by Padraic G. Fallon

Volume 667

**LIPID A IN CANCER THERAPY**

Edited by Jean-François Jeannin

Volume 668

**SUPERMEN1**

Edited by Katalin Balogh, and Attila Patocs

---

A Continuation Order Plan is available for this series. A continuation order will bring delivery of each new volume immediately upon publication. Volumes are billed only upon actual shipment. For further information please contact the publisher.

# **SuperMEN1: Pituitary, Parathyroid and Pancreas**

Edited by

**Katalin Balogh, MD, PhD**

*2nd Department of Medicine, Faculty of Medicine, Semmelweis University,  
Budapest, Hungary*

**Attila Patocs, MD, MSc, PhD**

*Hungarian Academy of Sciences Molecular Medicine Research Group  
and 2nd Department of Medicine, Faculty of Medicine, Semmelweis University  
Budapest, Hungary*

**Springer Science+Business Media, LLC**

**Landes Bioscience**

Springer Science+Business Media, LLC  
Landes Bioscience

Copyright ©2009 Landes Bioscience and Springer Science+Business Media, LLC

All rights reserved.

No part of this book may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher, with the exception of any material supplied specifically for the purpose of being entered and executed on a computer system; for exclusive use by the Purchaser of the work.

Printed in the USA.

Springer Science+Business Media, LLC, 233 Spring Street, New York, New York 10013, USA  
<http://www.springer.com>

Please address all inquiries to the publishers:  
Landes Bioscience, 1002 West Avenue, Austin, Texas 78701, USA  
Phone: 512/ 637 6050; FAX: 512/ 637 6079  
<http://www.landesbioscience.com>

The chapters in this book are available in the Madame Curie Bioscience Database.  
<http://www.landesbioscience.com/curie>

*SuperMEN1: Pituitary, Parathyroid and Pancreas*, edited by Katalin Balogh and Attila Patocs.  
Landes Bioscience / Springer Science+Business Media, LLC dual imprint / Springer series: Advances in Experimental Medicine and Biology.

ISBN: 978-1-4419-1662-4

While the authors, editors and publisher believe that drug selection and dosage and the specifications and usage of equipment and devices, as set forth in this book, are in accord with current recommendations and practice at the time of publication, they make no warranty, expressed or implied, with respect to material described in this book. In view of the ongoing research, equipment development, changes in governmental regulations and the rapid accumulation of information relating to the biomedical sciences, the reader is urged to carefully review and evaluate the information provided herein.

**Library of Congress Cataloging-in-Publication Data**

SuperMEN1 : pituitary, parathyroid, and pancreas / [edited by] Katalin Balogh, Attila Patocs.  
p. ; cm. -- (Medical intelligence unit) (Advances in experimental medicine and biology ; v. 668)  
Includes bibliographical references and index.  
ISBN 978-1-4419-1662-4

1. Endocrine glands--Tumors. 2. Pituitary gland--Tumors. 3. Parathyroid glands--Tumors. 4. Pancreas--Tumors. I. Balogh, Katalin, 1977- II. Patocs, Attila, 1973- III. Series: Medical intelligence unit (Unnumbered : 2003)

[DNLM: 1. Multiple Endocrine Neoplasia Type 1--physiopathology. 2. Pancreatic Neoplasms--etiology. 3. Parathyroid Neoplasms--etiology. 4. Pituitary Neoplasms--etiology. 5. Tumor Suppressor Proteins--metabolism. WK 140 S959 2009]

RC280.E55S87 2009

616.99'44--dc22

2009028832.

## **PREFACE**

The vast expansion in research on tumorigenesis has greatly increased our understanding of tumor development in patients with inherited endocrine tumor syndromes. This book provides an up-to-date summary from clinical basics and latest follow-up guidelines to the most recent molecular findings in multiple endocrine neoplasia Type 1 syndrome. Articles have been assembled by acknowledged experts in their respective fields to provide current perspectives on the clinical and genetic backgrounds of this syndrome and to review carefully the latest discoveries concerning the possible functions and interactions of menin, the protein encoded by the *MEN1* gene, including its possible role in cell cycle regulation, hematopoiesis, and bone development. The goal of the book is also to present the most recent findings and the broadest aspects of the role of menin in tumorigenesis of the endocrine glands involved in MEN 1 syndrome (pituitary, parathyroid, endocrine pancreas and adrenal). The connection between the basic experimental and clinical points of view are highlighted through a discussion on animal models, which explores the field in both an inspiring and questioning manner with a focus on areas that remain to be clarified. Our goal was to bring together clinicians and basic researchers who represent a wide range of interests in this particular field of endocrine oncology. Presenting a comprehensive and current overview of basic experimental and clinical findings, this book can bring us closer to understanding endocrine tumorigenesis in multiple endocrine neoplasia Type 1.


*Katalin Balogh, MD, PhD  
Attila Patocs, MD, MSc, PhD*

## **ABOUT THE EDITORS...**



**KATALIN BALOGH, MD, PhD:** I graduated from Semmelweis University, Budapest as a Medical Doctor in 2001 and defended my PhD thesis on the clinical and genetic aspects of multiple endocrine neoplasia Type 1 in 2007. Working as a student at the Department of Physiology, then as a physician at the 2nd Department of Medicine, Semmelweis University, Budapest, I always had the inspiration to build bridges between patients, clinicians and researchers. Being a part of connecting different fields of medicine has always been and still remains a challenge for me. My main research interest is endocrine oncology, I am a member of the Endocrine Society and an international scholarship has afforded me the opportunity to work as a research fellow in Toronto. I hope to continue to build connections between people, continents and nations.

## **ABOUT THE EDITORS...**



**ATTILA PATOCS MD, MSc, PhD:** I completed my medical and PhD training at Semmelweis University, Budapest, Hungary in 1998 and 2005, respectively. My interest has always focused on experimental laboratory work; therefore I attended and completed a biomedical engineering training at the Budapest Technical University in 2000. Between 2005-2007 I participated in a two-year postdoctoral fellowship in Dr. Charis Eng's laboratory at the Comprehensive Cancer Center of the Ohio State University and at the Genomic Medicine Institute of the Cleveland Clinic. Back in my home country from 2008 I am head of the Central Isotope Diagnostic Laboratory at the Semmelweis University and as a research associate I am working with the Molecular Medicine Research Group of the Hungarian Academy of Sciences. My research focuses on genetic and genomic characterization of endocrine tumors, on understanding of glucocorticoid signaling and on development of new, routine and molecular biological laboratory methods for diagnosis of endocrine disorders.

## PARTICIPANTS

Amar Agha  
Academic Department of Endocrinology  
Beaumont Hospital and Royal College  
of Surgeons in Ireland Medical School  
Dublin  
Ireland

Dheepa Balasubramanian  
Department of Genetics  
Case Western Reserve University  
Cleveland, Ohio  
USA

Katalin Balogh  
2nd Department of Medicine  
Faculty of Medicine  
Semmelweis University  
Budapest  
Hungary

Pierre-André Bédard  
Department of Biology  
McMaster University  
Hamilton, Ontario  
Canada

Lucie Canaff  
Departments of Medicine Physiology  
and Human Genetics  
McGill University, and Calcium  
Research Laboratory and Hormones  
and Cancer Research Unit  
Royal Victoria Hospital  
Montreal, Quebec  
Canada

Herbert Chen  
Chief of Endocrine Surgery  
Section of Endocrine Surgery  
Department of Surgery  
The University of Wisconsin  
University of Wisconsin Comprehensive  
Cancer Center  
Madison, Wisconsin  
USA

Colin Davenport  
Academic Department of Endocrinology  
Beaumont Hospital and Royal College  
of Surgeons in Ireland Medical School  
Dublin  
Ireland

Patrick Gaudray  
Génétique, Immunothérapie, Chimie  
et Cancer (GICC)  
Université François Rabelais  
and  
Faculté des Sciences et Techniques,  
Parc de Grandmont  
Tours  
France

Geoffrey N. Hendy  
Calcium Research Laboratory  
Royal Victoria Hospital  
Montreal, Quebec  
Canada



Jay L. Hess  
 Department of Pathology  
 University of Michigan Medical School  
 Ann Arbor, Michigan  
 USA

Peter Igaz  
 2nd Department of Medicine  
 Faculty of Medicine  
 Semmelweis University  
 Budapest  
 Hungary

Hiroshi Kaji  
 Division of Diabetes  
 Metabolism and Endocrinology  
 Department of Internal Medicine  
 Kobe University Graduate School  
 of Medicine  
 Kobe  
 Japan

Terry C. Lairmore  
 Department of Surgery  
 Division of Surgical Oncology  
 Scott and White Memorial Hospital  
 Clinic  
 Texas A&M University System Health  
 Sciences Center College of Medicine  
 Temple, Texas  
 USA

Jean-Jacques Lebrun  
 Hormones and Cancer Research Unit  
 Department of Medicine  
 Royal Victoria Hospital  
 McGill University  
 Montreal, Quebec  
 Canada

Ivan Maillard  
 Department of Pathology  
 University of Michigan Medical School  
 Ann Arbor, Michigan  
 USA

Bart M. Maslikowski  
 Department of Biology  
 McMaster University  
 Hamilton, Ontario  
 Canada

Maria Papaconstantinou  
 Department of Biology  
 McMaster University  
 Hamilton, Ontario  
 Canada

Attila Patocs  
 Hungarian Academy of Sciences  
 Molecular Medicine Research Group  
 and 2nd Department of Medicine  
 Faculty of Medicine  
 Semmelweis University  
 Budapest  
 Hungary

Alicia N. Pepper  
 Department of Biology  
 McMaster University  
 Hamilton, Ontario  
 Canada

Karoly Racz  
 2nd Department of Medicine  
 Semmelweis University  
 Budapest  
 Hungary

Peter C. Scacheri  
 Department of Genetics  
 Case Western Reserve University  
 Cleveland, Ohio  
 USA

Günther Weber  
 Génétique, Immunothérapie, Chimie  
 et Cancer (GICC)  
 Université François Rabelais  
 and  
 CNRS UMR 6239  
 Faculté des Sciences et Techniques  
 Tours  
 France

# CONTENTS

## 1. MEN1 CLINICAL BACKGROUND ..... 1

Peter Igaz

Abstract.....	1
Introduction.....	1
Clinical Features .....	2
Diagnosis of MEN1 .....	6
MEN1 Variants and Phenocopy.....	6
Diagnostics of MEN1-Related Tumors.....	8
Screening for MEN1 Manifestations .....	9
Indications for <i>MEN1</i> Germline Mutation Screening .....	9
Therapy.....	11
Surveillance .....	12
Comments and Conclusion.....	12

## 2. GENETIC BACKGROUND OF MEN1: FROM GENETIC HOMOGENEITY TO FUNCTIONAL DIVERSITY..... 17

Patrick Gaudray and Günther Weber

Abstract.....	17
Introduction: The History of a Rare Endocrine Genetic Disease.....	17
On the Nature of the <i>MEN1</i> Gene .....	18
On the Regulation of the <i>MEN1</i> Gene.....	20
What Do We Learn from the Hereditary Mutations of the <i>MEN1</i> Gene? .....	21
Importance of MEN1 in Endocrine Tumorigenesis .....	21
Is MEN1 a Genome Instability Syndrome? .....	22
Conclusion .....	23

## 3. MENIN: THE PROTEIN BEHIND THE MEN1 SYNDROME ..... 27

Maria Papaconstantinou, Bart M. Maslikowski, Alicia N. Pepper  
and Pierre-André Bédard

Abstract.....	27
Introduction.....	27
Menin Is a Nuclear Protein—Role of the C-Terminal Region .....	27

<b>Leucine-Rich Domains in Menin .....</b>	<b>29</b>
<b>GTPase Signature Motif.....</b>	<b>30</b>
<b>Post-Translational Modification in Response to DNA Damage .....</b>	<b>30</b>
<b>Conservation of Menin Structure, Protein Interactions and Function.....</b>	<b>30</b>
<b>Conclusion .....</b>	<b>33</b>
<b>4. CELLULAR FUNCTIONS OF MENIN.....</b>	<b>37</b>
Geoffrey N. Hendy, Hiroshi Kaji and Lucie Canaff	
<b>Abstract.....</b>	<b>37</b>
<b>Introduction.....</b>	<b>37</b>
<b>Cell Cycle .....</b>	<b>37</b>
<b>Cell Cycle Checkpoints and DNA Repair .....</b>	<b>43</b>
<b>Chromatin Remodeling .....</b>	<b>45</b>
<b>Conclusion .....</b>	<b>47</b>
<b>5. THE ROLE OF MENIN IN HEMATOPOIESIS.....</b>	<b>51</b>
Ivan Maillard and Jay L. Hess	
<b>Abstract.....</b>	<b>51</b>
<b>Introduction.....</b>	<b>51</b>
<b>Role of Menin in Hematopoiesis .....</b>	<b>53</b>
<b>Role of Menin in Leukemogenesis .....</b>	<b>54</b>
<b>Conclusion .....</b>	<b>55</b>
<b>6. ROLE OF MENIN IN BONE DEVELOPMENT .....</b>	<b>59</b>
Hiroshi Kaji, Lucie Canaff and Geoffrey N. Hendy	
<b>Abstract.....</b>	<b>59</b>
<b>Introduction.....</b>	<b>59</b>
<b>Menin and TGF-<math>\beta</math> Signaling .....</b>	<b>59</b>
<b>Menin and AP-1 Signaling.....</b>	<b>60</b>
<b>BMP, TGF-<math>\beta</math> and AP-1 Signaling in the Osteoblast.....</b>	<b>60</b>
<b>Role of Menin in Early Stage Osteoblast Differentiation .....</b>	<b>62</b>
<b>Menin and TGF-<math>\beta</math> Pathway in Osteoblast Differentiation .....</b>	<b>62</b>
<b>Menin and JunD in the Osteoblast.....</b>	<b>64</b>
<b>Conclusion .....</b>	<b>65</b>
<b>7. ACTIVIN, TGF-<math>\beta</math> AND MENIN IN PITUITARY TUMORIGENESIS ....</b>	<b>69</b>
Jean-Jacques Lebrun	
<b>Abstract.....</b>	<b>69</b>
<b>Introduction.....</b>	<b>69</b>
<b>The Activin/TGF-<math>\beta</math> Superfamily.....</b>	<b>71</b>
<b>Activin/TGF-<math>\beta</math> in the Pituitary .....</b>	<b>72</b>
<b>Activin Inhibits Prolactin Gene Expression and Signalling.....</b>	<b>72</b>
<b>Loss of Menin Inhibits TGF-<math>\beta</math> Induced Transcriptional Activity.....</b>	<b>73</b>
<b>Menin Interacts with Smad Proteins.....</b>	<b>73</b>
<b>Smads and Menin Are Required for Activin-Mediated Cell Growth Inhibition and Repression of Prolactin Gene Expression.....</b>	<b>74</b>
<b>Conclusion .....</b>	<b>75</b>

<b>8. THE ROLE OF MENIN IN PARATHYROID TUMORIGENESIS .....</b>	<b>79</b>
Colin Davenport and Amar Agha	
<b>Abstract.....</b>	<b>79</b>
<b>Introduction.....</b>	<b>79</b>
<b>The <i>MEN1</i> Gene.....</b>	<b>79</b>
<b><i>MEN1</i> Related Mutations and Menin Expression in Hereditary and Sporadic Hyperparathyroidism (Genotype-Phenotype Correlation).....</b>	<b>82</b>
<b>TGF-<math>\beta</math>/Smad3 Signalling.....</b>	<b>83</b>
<b>Menin and TGF-<math>\beta</math> Signalling .....</b>	<b>83</b>
<b>Other Forms of Parathyroid Tumorigenesis .....</b>	<b>85</b>
<b>Conclusion .....</b>	<b>85</b>
<b>9. ROLE OF MENIN IN NEUROENDOCRINE TUMORIGENESIS.....</b>	<b>87</b>
Terry C. Lairmore and Herbert Chen	
<b>Abstract.....</b>	<b>87</b>
<b>Introduction.....</b>	<b>87</b>
<b>Global Gene Expression in Normal Islet Cells versus MEN 1-Associated Neuroendocrine Tumors .....</b>	<b>88</b>
<b>Signaling Pathways in Neuroendocrine Tumors .....</b>	<b>90</b>
<b>Treatment of Neuroendocrine Tumors Based on Molecular Genetic Diagnosis .....</b>	<b>92</b>
<b>10. ADRENAL TUMORS IN MEN1 SYNDROME AND THE ROLE OF MENIN IN ADRENAL TUMORIGENESIS .....</b>	<b>97</b>
Attila Patocs, Katalin Balogh and Karoly Racz	
<b>Introduction.....</b>	<b>97</b>
<b>Genetics of Adrenal Tumors.....</b>	<b>97</b>
<b>Hereditary Syndromes with Adrenal Involvement .....</b>	<b>97</b>
<b>Somatic Genomics of Sporadic Adrenal Tumors .....</b>	<b>98</b>
<b>MEN1-Associated Adrenal Tumors .....</b>	<b>99</b>
<b>Diagnosis, Therapy and Follow-Up of Adrenal Tumors.....</b>	<b>100</b>
<b><i>MEN1</i> Gene Mutation Screening in Patients with Adrenal Tumors: To Screen or Not? .....</b>	<b>101</b>
<b>Comments and Conclusion.....</b>	<b>102</b>
<b>11. FUNCTIONAL STUDIES OF MENIN THROUGH GENETIC MANIPULATION OF THE <i>MEN1</i> HOMOLOG IN MICE .....</b>	<b>105</b>
Dheepa Balasubramanian and Peter C. Scacheri	
<b>Abstract.....</b>	<b>105</b>
<b>Introduction.....</b>	<b>105</b>
<b>Conventional <i>Men1</i> Mouse Models .....</b>	<b>106</b>
<b>Conditional <i>Men1</i> Mouse Mutants .....</b>	<b>108</b>
<b>Menin Overexpression .....</b>	<b>110</b>
<b>Crossbreeding Studies .....</b>	<b>111</b>
<b>Conclusion .....</b>	<b>112</b>
<b>INDEX.....</b>	<b>117</b>

## **ACKNOWLEDGEMENTS**

Finally, the editors would like to acknowledge all the authors and colleagues who have contributed in various ways to this book, and we would like to express our appreciation to the staff at Landes Bioscience for their cooperation.